Clinical Trial Update: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase II study of pertuzumab in combination with erlotinib for metastatic or unresectable neuroendocrine tumors was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Gland Tumors
• Carcinoid Tumors
• Multiple Endocrine Neoplasia
• Neuroblastoma
• Neuroendocrine Tumors
• Pancreatic Neuroendocrine Tumors

Drugs mentioned

• Perjeta (pertuzumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Pamela L. Kunz | Conditions: Neuroendocrine Tumors, Carcinoid Tumors | Phase 2 | Status: TERMINATED | Results posted: 2017-03-03